Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH)
Many adolescents with X-linked hypophosphatemia (XLH) currently have to stop treatment with burosumab at the end of skeletal growth. We describe the experience of a cohort of adolescents with XLH before, during, and after stopping burosumab (median treatment duration 37.5 months). Improvements in serum phosphate, pain, mobility, function, and quality of life noted during burosumab treatment were reversed after treatment cessation. Further real-world data are needed to explore the value of uninterrupted burosumab treatment in adolescents.
Authors
- Sanjay Gupta (ORCID: https://orcid.org/0000-0001-7001-0130)
- Annabel Nixon (ORCID: https://orcid.org/0000-0003-3454-9491)
- Talat Mushtaq (ORCID: https://orcid.org/0000-0002-9890-7369)
- Suma Uday (ORCID: https://orcid.org/0000-0002-7278-0734)
- Angela Rylands (ORCID: https://orcid.org/0000-0002-7790-4724)
- Charlotte Jarvis (ORCID: https://orcid.org/0000-0002-3513-5840)
- Renuka Ramakrishnan (ORCID: https://orcid.org/0000-0002-9864-5303)
- Poonam Dharmaraj (ORCID: https://orcid.org/0000-0002-2249-1862)
- Angela Williams
- Helen Barham
Institutions
- University of Hull (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Salisbury District Hospital (GB)
- Alder Hey Children's NHS Foundation Trust (GB)
- Kyowa Kirin International (United Kingdom) (GB)
- Birmingham Women’s and Children’s NHS Foundation Trust (GB)
Publication Details
- Journal
- Bone Reports
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1016/j.bonr.2024.101819
- Citations
- 7
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.37